Patients & Families

Congenital Adrenal Hyperplasia

Congenital adrenal hyperplasia (CAH) refers to a group of genetic conditions that result in an enzyme deficiency that alters the production of adrenal hormones. Approximately 95% of CAH cases are caused by a mutation that leads to deficiency of the enzyme 21-hydroxylase. In classic CAH, severe deficiency of this enzyme leads to an inability of the adrenal glands to produce cortisol and, in approximately 75% of cases, aldosterone.

If left untreated, classic CAH can result in salt wasting, dehydration, and even death. Even with cortisol replacement, high levels of adrenocorticotropic hormone (ACTH) from the pituitary gland result in excess androgen production leading to virilization and menstrual irregularities in females. Both males and females with classic CAH can experience problems with growth and development in childhood including early puberty, short stature or height below genetic potential, and fertility problems in adulthood.

Classic CAH is estimated to affect approximately 30,000 people in the U.S. and 50,000 people in Europe.

There are currently no non-steroidal treatments approved by the U.S. Food and Drug Administration (FDA) for classic CAH. Glucocorticoids, the current standard of care, are used to correct the endogenous cortisol deficiency and to try and reduce the high ACTH levels and androgen excess. However, the dose and duration of steroid use required to try and control androgen excess is generally well above the normal physiological level of cortisol, which can result in serious and common complications of steroid excess, including metabolic abnormalities, bone loss, growth impairment, and iatrogenic Cushing’s syndrome.

CAHtalog™ Registry: A New CAH Patient Registry

The CARES Foundation, partnering with Neurocrine Biosciences and PicnicHealth, has established the CAHtalog™ (Congenital Adrenal Hyperplasia: Patient and Clinical Outcomes in Real-World Practice Settings) Registry. The goal of the registry is to support patient-centered research that will enhance the scientific community’s foundational knowledge of CAH and ultimately improve the lives of patients who live with it every day. Participants can contribute to CAH research and share their unique patient journey and voice without the need for in-person visits. After enrollment, participants will have ready access to their digital medical records in one place. To learn more about the CAHtalog™ Registry and how to participate, click here.

Pipeline

At Neurocrine Biosciences, we have a robust pipeline of investigational therapies with the potential to address unmet clinical needs of patients living with neurological, endocrine and psychiatric disorders.

Learn More
Products

While others walk away from neuroscience because of risk and complexity, our team persists, resulting in four FDA-approved therapies.

Learn More